National heart foundation of australia and cardiac society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018

Medical Journal of Australia

Volumn 209, Issue 8, 2018, Pages 356-362

  Brieger, David ^a   Amerena, John ^b   Attia, John R ^c,d   Bajorek, Beata ^e   Chan, Kim H ^f,g   Connell, Cia ^h   Freedman, Ben ^g   Ferguson, Caleb ^i,j   Hall, Tanya ^k   Haqqani, Haris M ^l   Hendriks, Jeroen ^m,n   Hespe, Charlotte M ^o   Hung, Joseph ^p   Kalman, Jonathan M ^q,r   Sanders, Prashanthan ^m,n   Worthington, John ^f   Yan, Tristan ^f   Zwar, Nicholas A ^s  

^a ANZAC Research Institute   (Australia)

^b UNIVERSITY HOSPITAL GEELONG   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

ⁱ UNIVERSITY OF WESTERN SYDNEY   (Australia)

^j BLACKTOWN HOSPITAL   (Australia)

^k Hearts4Heart   (Australia)

^l THE PRINCE CHARLES HOSPITAL   (Australia)

^m ROYAL ADELAIDE HOSPITAL   (Australia)

ⁿ UNIVERSITY OF ADELAIDE   (Australia)

^o UNIVERSITY OF NOTRE DAME   (Australia)

^p SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^q UNIVERSITY OF MELBOURNE   (Australia)

^r ROYAL MELBOURNE HOSPITAL   (Australia)

^s UNIVERSITY OF WOLLONGONG   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DABIGATRAN; DIGOXIN; DILTIAZEM; ESMOLOL; FLECAINIDE; METOPROLOL; RIVAROXABAN; SOTALOL; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; AUSTRALIA AND NEW ZEALAND; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHA2DS2-VASC SCORE; CORONARY ARTERY BYPASS GRAFT; ELECTROCARDIOGRAM; EVIDENCE BASED PRACTICE; HEART SURGERY; HEMODYNAMICS; HUMAN; INTEGRATED HEALTH CARE SYSTEM; INTERNATIONAL NORMALIZED RATIO; POINT OF CARE TESTING; PRACTICE GUIDELINE; PROPHYLAXIS; RISK ASSESSMENT; SCREENING; AUSTRALIA; NEW ZEALAND;

ATRIAL FIBRILLATION; AUSTRALIA; HUMANS; NEW ZEALAND;

EID: 85054715302     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja18.00646     Document Type: Article

References (52)

1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962.
2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130(23): 2071-2104.
3. Brieger D, Amarena J, Attia J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ 2018; https://doi.org/10.1016/j.hlc. 2018.06.1043.
4. Schünemann H, Brozek J, Guyatt G, Oxman A, editors. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. http://gdt.guidelinedevelopment.org/app/handbook/handbook.html (viewed Feb 2018).
5. Mahajan R, Perera T, Elliott AD, et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J 2018; 39: 1407-1415.
6. Freedman B, Boriani G, Glotzer TV, et al. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 2017; 14: 701-714.
7. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options e a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012; 14: 8-27.
8. Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91: 265-325.
9. Chamberlain AM, Agarwal SK, Folsom AR, et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011; 107: 85-91.
10. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
11. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49: 565-571.
12. Tedrow UB, Conen D, Ridker PM, et al. The long-and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women’s health study). J Am Coll Cardiol 2010; 55: 2319-2327.
13. Lau DH, Middeldorp ME, Brooks AG, et al. Aortic stiffness in lone atrial fibrillation: a novel risk factor for arrhythmia recurrence. PLoS One 2013; 8: e76776.
14. Mozaffarian D, Furberg CD, Psaty BM, et al. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation 2008; 118: 800-807.
15. Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 2014; 7: 620-625.
16. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013; 310: 2050-2060.
17. Schreck, DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997; 29: 135-140.
18. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000; 49: 47-59.
19. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992; 70: 69-72.
20. Chevalier P, Durand-Dubief A, Burri H, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41: 255-262.
21. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
22. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913-920.
23. The Atrial Fibrillation Follow-up Investigation of Rhythm Management Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
24. Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015; (3): CD005049.
25. McNamara RL, Tamariz LJ, Segal JB, et al. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139: 1018-1033.
26. Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1999; 84: 270-277.
27. Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385-1394.
28. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993; 72(4): 44a-50a.
29. Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013; 6: 479-487.
30. Kalla M, Sanders P, Kalman JM, et al. Radiofrequency catheter ablation for atrial fibrillation: approaches and outcomes. Heart Lung Circ 2017; 26: 941-949.
31. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018; 378: 417-427.
32. Voskoboinik A, Sparks PB, Morton JB, et al. Low rates of major complications for radiofrequency ablation of atrial fibrillation maintained over 14 years: a single centre experience of 2750 consecutive cases. Heart Lung Circ 2018; 27: 976-983.
33. Cherniavsky A, Kareva Y, Pak I, et al. Assessment of results of surgical treatment for persistent atrial fibrillation during coronary artery bypass grafting using implantable loop recorders. Interact Cardiovasc Thorac Surg 2014; 18: 727-731.
34. Ad N, Henry L, Hunt S, et al. Do we increase the operative risk by adding the Cox Maze III procedure to aortic valve replacement and coronary artery bypass surgery? J Thorac Cardiovasc Surg 2012; 143: 936-944.
35. Damiano RJ Jr, Gaynor SL, Bailey M, et al. The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. J Thorac Cardiovasc Surg 2003; 126: 2016-2021.
36. Geidel S, Lass M, Krause K, et al. Persistent atrial fibrillation ablation concomitant to coronary surgery. Thorac Cardiovasc Surg 2011; 59: 207-212.
37. Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2015; 38: 555-561.
38. Chiang C-E, Wu T-J, Ueng K-C, et al. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formosan Med Assoc 2016; 115: 893-952.
39. Goldsmith K, Balabanski A, Giarola B, et al. RACP trainee awards for excellence in the field of adult medicine. Intern Med J 2017; 47: 7.
40. Al-Kawaz M, Omran SS, Parikh NS, et al. Comparative risks of ischemic stroke in atrial flutter versus atrial fibrillation. J Stroke Cerebrovasc Dis 2018; 27: 839-844.
41. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147: 590-592.
42. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
43. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
44. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
45. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
46. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
47. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917.
48. Guo Y, Chen Y, Lane D, et al. Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF app trial. Am J Med 2017; 130: 1388-1396.e6.
49. Pandya E, Bajorek BV. Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation. J Clin Pharm Therapeut 2016; 41: 667-676.
50. Simons LA, Ortiz M, Freedman B, et al. Medium-to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience. Curr Med Res Opin 2017; 33: 1337-1341.
51. Abdou JK, Auyeung V, Patel JP, et al. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol 2016; 174: 30-42.
52. Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev 2013; (6): CD008600.